California-based AI firm Suki has raised $70 million in new funding, led by Hedosophia, bringing its total to $165 million.

Swiss generic and biosimilar medicines major Sandoz today announced that it has launched a generic paclitaxel formulation in ...

Pfizer is set to present initial findings from its CULTIVATE study of Velsipity (etrasimod) in Crohn’s disease (CD) at UEG ...

The UK's MHRA has approved Pfizer and BioNTech's updated COVID-19 vaccine, Comirnaty (KP.2), for use in adults. This approval ...

Switzerland-based KeyBioscience and US pharma major Eli Lilly have extended their collaboration on dual amylin calcitonin ...

South Korea’s Samsung Bioepis has released its Fourth Quarter 2024 Biosimilar Market Report, marking the seventh-edition of ...

The Food and Drug Administration (FDA) approved Genentech's Itovebi (inavolisib), in combination with palbociclib (Ibrance) ...

German cancer specialist Immatics has priced a $150 million public offering with Jefferies, BofA Securities, and Leerink as ...

Berlin, Germany-based Booster Therapeutics, a biotechnology company pioneering a new class of proteasome activator medicines ...

Two US units of Israel’s Teva Pharmaceutical Industries have agreed to pay $450 million to resolve two matters that allege Teva violated the Anti-Kickback Statute (AKS) and the False Claims Act (FCA), ...

Danish dermatology specialist Leo Pharma has revealed plans to cut more jobs, marking the company’s fourth workforce ...

Cambridge, Massachusetts-based RNA specialist CAMP4 Therapeutics (Nasdaq: CAMP) is set to raise $75 million as it goes public ...